ADISNEWS (Adis Newsletters)
Subject
Coverage

Important developments in drugs and drug therapy including:• Adverse drug reactions• Pharmacoeconomics and outcomes• Disease management• Pharmacoepidemiology• Pharmaceutical research and• Pharmacology
development• Therapeutics

File Type

Bibliographic, Full Text

Features

Alerts (SDI)

Weekly (default), or monthly

CAS Registry
Number® IdentifiersPage Images

Keep & Share




SLART




Learning Database

RecordContent

•
•
•
•
•
•

Structures

Bibliographic information
Full text of the reports
References to the documents cited by the newsletter
Indexing terms
Chemical names
CAS Registry Numbers

File SizeMore than 302,781 (10/22)

Coverage

1983 to the present

Updates

WeeklyLanguage

English

Database
Producer

Springer Nature Switzerland AG
Copyright Holder
Contact Springer Online Services support desk:
Email: onlineservice@springer.com
Phone: +49 6221 345 4303 (Europe/Asia/Africa)+1 800 777 4643 (North & South America)

Sources• Inpharma® - alerts to drugs and drug therapy (1994-2008)• ReactionsTM - alerts to adverse drug reactions from all adverse drug events reported
in the world's biomedical literature (1983 - present)• Pharmacoeconomics & Outcomes NewsTM - complete health economics news service
1995-2021)

User Aids• Online Helps (HELP DIRECTORY lists all help messages available)• STNGUIDE

October 2022

2
ADISNEWS

Clusters

October 2022

• ADISBASES• ALLBIB• BIOSCIENCE• CASRNS• FULLTEXT• HEALTH• MEDICINE• PHARMACOLOGY• PV• TOXICOLOGYSTN Database Clusters information (PDF).

3
ADISNEWS

Search and Display Field Codes
Simultaneous left and right truncation (SLART) may be used for search terms in the (/BI, /CW, /TI, and /TX)
fields and are marked with an asterisk.
Search Field Name

SearchCode

Display
Codes

Search Examples

Basic Index* (contains single
words from the title (TI),
chemical name (RN), controlled
term (CT), and text (TX) fields,
as well as CAS Registry
Numbers (RN))

None(or /BI)S NRT
S RELEAS? HORMONES SERIOUS (L) CASE REPORT#S 57-88-5

Accession Number
Chemical Name
Cited Reference (contains
referenced author or company
name, publication year,
volume, and first page)
Cited Reference Author Name
(Cited Reference Company
Name)
Cited Reference Country of
Publication
Cited Reference Document Type
Cited Reference Language
Cited Reference Page Number(1)
Cited Reference Publication
Name
Cited Reference Publication
Year (2)Cited Reference Series Volume
NumberCited Reference Title
Controlled Term

/AN
/CN
/RE

S 2001:1236/AN
S DC 015/CN
S ABDULLA S, 1998, V351, P1411?/RES ABBOTT LAB?/RE

AN
RN
RE

/RAU

RE

/RCY

S RILEY L?/RAU
S 3M?/RAU
S (GEORGE J? (L) LEACH J?)/RAU
S SINGAPORE/RCY

/RDT
/RLA
/RPG

S CORRESPONDENCE/RDTS NEWS ITEM/RDT (L) ENGLISH/RLAS 9-10/RPG

RE
RE
RE

/RWK

S WALL STREET JOURNAL/RWK

RE

/RPY

S RPY>=2000

RE

/RVL

S 998/RVL (L) 9/RPG

RE

/RTI
/CT

RE
CT

Controlled Word* (1)/CWDocument Number
Document Type (code)/DN/DT(or/TC)
/ED
/FA
/FS

S (MILD (L) ASTHMA)/RTIS ABACAVIR?/CTS BY-841, PHARMACODYNAMICS/CTS DIABETES/CWS SERIOUS REACTIONS/CWS 11735503-800244211/DN
S MIX/DT
S L1 and ED>=20010731
S L7 and RN/FAS INP/FSS INPHARMA/FS
S 1173-5503/ISN

ED
Not displayedFS

S REACTIONS/JTS JULY 30, 2001/PD
S 2000-2001/PY
S (INPHARMA AND 2001)/SO
S 1173-8324/SO
S TOLERATED DOS?/TX
S HEPATITIS/TIS PRODUCT NEWS/TI
S L1 AND UP>=20010900
S ADR AND WC<=100

JT, SOPD, SO
PD, PY, SO
SO

Entry Date (2)Field Availability (code and text)
File Segment (code and text)
International Standard(Document) Number (contains
ISSN)
Journal Title
Publication Date (2)Publication Year (2)Source (contains newsletter,publication date, and ISSN)
Text*
Title*/ISN

Update Date (2)Word Count (of text) (2)

/UP
/WC

/JT
/PD
/PY
/SO
/TX
/TI

RN, TI, TX

RE

CT
DN
DT

ISN, SO

TX
TI
UP
WC

(1) Search with implied (S) proximity is available in this field.
(2) Numeric search field that may be searched using numeric operators or ranges.
October 2022

4
ADISNEWSDISPLAY and PRINT Formats
Any combination of formats may be used to display or print answers. Multiple codes must be separated by
spaces or commas, e.g., D L1 1-5 TI TX. The fields are displayed or printed in the order requested.
Hit-term highlighting is available for all fields except PY. Highlighting must be ON during SEARCH in order to
use the HIT, KWIC, and OCC formats.
FormatContent

ExamplesAN (1)CT (1)
DN (1)DT (TC)ED
FS (2)ISN (2)JT (2)PD (2)
PY (2)RE
RN (CN) (1)SO
TI (1)TX
UP
WC

Accession Number
Controlled Term
Document Number
Document Type
Entry Date (includes UP)
File Segment
International Standard (Document) Number (ISSN)
Journal Title
Publication Date
Publication Year
Cited Reference
CAS Registry Number and Chemical Name
SourceTitle
Text
Update Date (includes ED)
Word Count

D AN
D 1-5 CT
D DN
D DT
D 1 8 EDD 1, 3-5 FS
D ISN
D JT 3D PD
D PY
D RE 10 7
D RN
D SO
D TI TOTAL
D TX
D UP
D WC 3,4

ALL
BIB
CBIB
DALL
IALL
IBIB

AN, ED, UP, DN, TI, SO, DT, WC, TX, RE, CT, RN
AN, ED, UP, DN, TI, SO, DT, WC
AN, DN, compressed bibliographic information
ALL. delimited for post processing
All, indented with text labels
BIB, indented with text labels(IBIB is the default)
IND, indented with text labels
CT, RN
BIB and hit terms in ORG, PHARM and IDE (Default display)
DN, TI (random display without answer numbers)
AN, DN, TI

D ALL
D BIB
D CBIBD DALLD IALLD IBIB L2 7

ALL, in XML format

D XML

Fields containing hit terms
Hit term with 20 words on either side (KeyWord-In-Context)
Number of occurrences of hit terms and fields in which they occur

D HIT
D KWIC NOH
D OCC 1-6

IIND (1)IND (1)QRD
SCAN (1,3)
TRIAL (TRI,
SAM,
FREE) (1)
XML
HIT
KWIC
OCC (1)(1) No online display fee for this format.
(2) Custom display only.
(3) SCAN must be specified on the command line, i.e., D SCAN or DISPLAY SCAN.

October 2022

D IINDD IND
D QRD
D SCAND FREE 1-25

5
ADISNEWS

Full-Text Browsing
User Request

ExampleSystem Response

DISPLAY BROWSE=> DISPLAY BROWSEENTER (L1) OR L#:.
ENTER (DIS), ANSWER NUMBERS, OR END:

NOVICE version

D BRO

EXPERT version

Answer number(s)=> D BRO L1::1-3

Answer number(s) and format
Format only

:4 HIT:TI TX

Change default format:*KWIC

Forward n fields
Backward n fields
Search forward for character
stringSearch backward for character
stringEnd DISPLAY BROWSE:F3:B1:S NICOTINE:S -NAUSEA:END=>

display answers 1, 2, and 3 indefault format
display answer 4 in HIT format
display title and text of lastanswer displayedchange default to KWIC
no answer displayed
move forward 3 fields
move backward 1 fieldsearch forward within record for'nicotine'
search backward within record
for 'nausea'
exit DISPLAY BROWSE andreturn to =>October 2022

6
ADISNEWSSELECT, ANALYZE, and SORT Fields
The SELECT command is used to create E-numbers containing terms taken from the specified field in ananswer set.
The ANALYZE command is used to create an L-number containing terms taken from the specified field in ananswer set.
The SORT command is used to rearrange the search results in either alphabetic or numeric order of thespecified field(s).
Field Name
Accession Number
CAS Registry Number
CAS Registry Number and Chemical Name
Chemical Name
Cited Reference
Cited Reference Publication NameControlled Term
Document Number
Document Type
Entry Date
File Segment
International Standard (Document) Number
Journal Title
Occurrence Count of Hit Terms
Publication Date
Publication Year
SourceText
Title
Treatment CodeUpdate Date
Word Count

Field CodeANALYZE/
SELECT (1)

SORT

AN
RN
CHEM
CN
NAME
RE
RWK
CT
DN
DT
ED
FS
ISN
JT
OCC
PD
PY
SO
TX
TI
TC
UP
WC

Y
Y (2)
Y (2)
Y
Y (2)
Y (3,4)
Y
Y
Y
Y
Y
Y
Y (5)
Y
N
Y
Y (3)
Y
Y
Y (default)
Y
Y
N

N
N
N
N
N
N
N
Y
Y
Y
Y
Y
N
Y
Y
Y
Y
N
N
Y
Y
Y
Y

(1) HIT may be used to restrict terms extracted to terms that match the search expression used to create the answer set, e.g., SEL HITCT.
(2) Appends /BI to the terms created by SELECT.
(3) SELECT HIT and ANALYZE HIT are not valid with this field.
(4) Extracts first author, publication year, volume, and first page with a truncation symbol appended and with /RE appended to the terms
created by SELECT.
(5) Selects or analyzes the ISSN and appends /ISN to the terms created by SELECT.

October 2022

7
ADISNEWS

Sample Records
DISPLAY IALL (INPHARMA Record)
ACCESSION NUMBER:
2008:8738 ADISNEWS Full-text
ENTRY DATE:Entered STN: 9 Dec 2008 Last Updated on STN: 9 Dec 2008
DOCUMENT NUMBER:
11738324-801133743
TITLE:
Product news: Laughter really is the best medicine.
SOURCE:
INPHARMA 9 Dec 2008 ISSN: 1173-8324
DOCUMENT TYPE:(MIX)WORD COUNT:
186
TEXT:
Laughter has always been considered the best medicine, and now there isresearch to prove it.
Rx Laughter, an organisation interested in using humour for healing, worked
with researchers from UCLA to determine the effect of humorous shows on thepain tolerance of children and adolescents undergoing stressful or painfulprocedures such as cancer treatments or blood draws.
Eighteen healthy children, aged 7 to 16 years, participated in the study inwhich they placed their hands into iced water for up to three minutes maximum.
Participants watched funny classic and contemporary shows and researchers took
a baseline measure of submersion duration before, during and after viewing of
the videos. The participants appraisals of pain and noted submersion times were
documented and examined in relation to humor indicators - the number oflaughs/smiles and the children's ratings of how funny the show was.
The group demonstrated significantly greater pain tolerance while viewing thefunny shows, but their ratings of the severity of the pain were not influenced.
These results suggest that humorous distraction could be used in clinicalsettings to help children better handle painful hospital procedures.
REFERENCE(S):(1) Medical News Today. Watching funny shows helps children tolerate pain for
longer periods. Internet Document 2007, P[2 pages] (English, Study (USA))CONTROLLED TERM:
ChildrenDISPLAY IALL (PHARMACOECONOMICS AND OUTCOMES NEWS Record)

ACCESSION NUMBER:
ENTRY DATE:DOCUMENT NUMBER:
TITLE:SOURCE:

2010:5804 ADISNEWS Full-text
Entered STN: 8 Oct 2010
Last Updated on STN: 8 Oct 2010
11735503-809116853
Chronic pain management inefficient in Europe.
PHARMACOECONOMICS AND OUTCOMES NEWS 8 Oct 2010
1173-5503
(MIX)
116

ISSN:

DOCUMENT TYPE:
WORD COUNT:TEXT:
A report, commissioned for inclusion in the European Pain Proposal*, has shownthat inefficiencies in the treatment of chronic pain leads to increased
healthcare costs and patient suffering.
The report found that there is a high degree of variability in accessing pain
management services, not only between but within countries. In addition, thetype of care offered is inconsistent. It says that both cost savings andimproved patient outcomes could be achieved if pain was managed efficiently andit calls on the European Union to provide a minimum standard of care for all
patients with chronic pain.
* developed by a group of European experts involved in chronic pain, policy andeconomics, in partnership with Pfizer
REFERENCE(S):(1) Pain Proposal. New Report Reveals Inefficient Management of Chronic Pain
Costs Billions of Euros Each Year. Media Release 2010, P29 Sep 2010.
Available from (English, Media release (Belgium))
CONTROLLED TERM:
Healthcare-expenditure; Healthcare-news; Pain, treatment
October 2022

8
ADISNEWSDISPLAY IALL (REACTIONS Record)
ACCESSION NUMBER:
ENTRY DATE:DOCUMENT NUMBER:
TITLE:

2010:5821 ADISNEWS Full-text
Entered STN: 8 Oct 2010
Last Updated on STN: 8 Oct 2010
01149954-803042187
ADR news: Natalizumab withdrawal. Immune reconstitution
inflammatory syndrome: case report. Serious.
REACTIONS 8 Oct 2010 ISSN: 0114-9954
(MIX)
273

SOURCE:DOCUMENT TYPE:
WORD COUNT:TEXT:
A 30-year-old woman with relapsing-remitting multiple sclerosis (MS) developed
experienced worsening of her condition due to immune reconstitution
inflammatory syndrome (IRIS) after her therapy with natalizumab was withdrawn.
The woman started receiving natalizumab at escalating doses with good response
after 22 infusions over almost 2 years [dosage details incomplete]. Natalizumab
was withdrawn in November 2008; at that time, she had an EDSS* score of 5. She
developed high-grade tetraparesis within the next 9 weeks despite administration of
methylprednisolone boli; additionally, new gadolinium-enhancing lesions became
evident on MRI.
The woman underwent forced immunotherapy with plasma exchange (PE). However,her condition worsened further with development of marked cognitive impairment,
neglect and consciousness disturbance; her EDSS score increased to 9.5. She
received further steroid pulses, but her symptoms persisted unchanged. Threemonths after natalizumab withdrawal, new development of gadolinium-enhancing
lesions on MRI continued. Proton magnetic resonance spectroscopy fromsubcortical white matter revealed a reduced N-acetylaspartate level, andincreased creatinine, choline and lactate levels. Her CSF cell count was
persistently elevated, intrathecal immunoglobulin synthesis was evident, and
her CD4+/CD8+ ratio was decreased. A brain biopsy showed an active
demyelinating lesion with immunopathological pattern and pronounced axonal
damage. She received another steroid pulse followed by a 3-week taper. At theend of the taper, her disease had spontaneously stabilised. Her condition
slowly improved, and she had an EDSS score of 7 in February 2010.
* Expanded Disability Status Scale
Author Comment: "PE was performed after estimated 4 to 6 half-times ofnatalizumab and thus by clearing
residual natalizumab might have accelerated lymphocyte trafficking into thebrain thereby paving the way for an IRIS-like rebound of inflammatory MS
activity."
REFERENCE(S):(1) Lenhard, T.; Biller, A.; Mueller, W.; Metz, I.; Schonberger, J.;
Wildemann, B. Immune reconstitution inflammatory syndrome after
withdrawal of natalizumab? Neurology 2010, V75, P831-833 (English, Case
report (Germany))
CONTROLLED TERM:
Drug-withdrawal; Immune-reconstitution-syndrome,
drug-induced; Multiple-sclerosis, drug-induced;
Natalizumab, serious adverse-reactions
CAS REGISTRY NO.:
60-27-5 (CREATININE)
62-49-7 (CHOLINE)
83-43-2 (METHYLPREDNISOLONE)
7440-54-2 (GADOLINIUM)
20846-91-7 (EDSS)In North America

In EMEAIn Japan

CAS Customer Center
P.O. Box 3012
Columbus, Ohio 43210-0012
U.S.A.

CAS Customer Center EMEA
(represented by FIZ Karlsruhe)
P.O. Box 2465
76012 Karlsruhe
Germany

JAICI (Japan Association forInternational Chemical Information)
Nakai Building
6-25-4 Honkomagome, Bunkyo-ku
Tokyo 113-0021
Japan

Phone:

800-753-4227 (North America)
614-447-3731 (worldwide)
Email:
help@cas.org
Internet: www.cas.org

October 2022

Phone: +49-7247-808-555
E-mail: EMEAhelp@cas.org

Phone:+81-3-5978-3601 (Technical Service)+81-3-5978-3621 (Customer Service)
Email:
support@jaici.or.jp (Technical Service)customer@jaici.or.jp (Customer Service)
Internet: www.jaici.or.jp